Pharmacological Inhibition of cAMP Signaling is an Attractive Therapeutic Strategy for Management of Chronic Inflammatory and Autoimmune Diseases
Journal of clinical & cellular immunology(2021)
摘要
Systemic Lupus Erythematosus (SLE) evolves into progressive and chronic inflammation of multiple joints and organs.
No specific treatment exists for SLE which presents a diverse clinical polymorphism with unclear pathogenicity.
Women at their pre-menopausal age are the most affected and early studies have reported the implication of estrogen
in T cell abnormalities. Alteration of cAMP signaling in immune cells and target organs is emerging as cellular
mechanism governing SLE disease progression. We recently reported that activity and expressions of PDE4, the
major cAMP hydrolyzing enzyme were deregulated in kidney of lupus prone mice. Therefore, PDE4 inhibitors
may exert anti-inflammatory effects on several immunocompetent cells including T and B lymphocytes, and
macrophages. Several PDE4 inhibitors achieved good therapeutic values as potent anti-inflammatory compounds
for the treatment of chronic inflammatory diseases including Crohn's disease, autoimmune disease (lupus), COPD,
and neurodegenerative diseases. This review will discuss the mechanism of NCS 613, a new cAMP elevating agent
in preventing systemic chronic inflammation in SLE. This PDE4 inhibitor is believed to reduce abnormal systemic
inflammation orchestrated by overreactive T cells that stimulate autoantibodies production by autoreactive B cells
and proinflammatory mediators release by macrophages. Ultimately, NCS 613 improve survival and overcome
nephritis in mice and prevent inflammatory cytokines release in human stimulated leucocytes. PDE4 inhibition is a
promising therapeutic target to tackle chronic inflammatory disease of different pathogenicity.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要